Next Article in Journal
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Next Article in Special Issue
A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16)
Previous Article in Journal
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
Previous Article in Special Issue
Mouse Lymphoblastic Leukemias Induced by Aberrant Prdm14 Expression Demonstrate Widespread Copy Number Alterations Also Found in Human ALL
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(4), 1161-1179; doi:10.3390/cancers4041161

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)

Department of Medicine and Oncology, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada
Department of Pathology and Cell Biology, Institute of Research in Immunology and Cancer (IRIC), Université de Montréal, Pavillion Marcelle-Coutu, Chemin Polytechnique, Montreal, QC, H3T 1J4, Canada
Authors to whom correspondence should be addressed.
Received: 22 August 2012 / Revised: 29 September 2012 / Accepted: 17 October 2012 / Published: 2 November 2012
(This article belongs to the Special Issue Leukemia)
View Full-Text   |   Download PDF [422 KB, uploaded 2 November 2012]


Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantial new laboratory findings over the past decade have identified many cellular pathways that contribute to leukemogenesis. These studies have led to the development of novel agents designed to target these pathways. Here we discuss the molecular underpinnings and clinical benefits of these novel treatment strategies. Most importantly these studies demonstrate that clinical response is best achieved by stratifying each patient based on a detailed understanding of their molecular abnormalities.
Keywords: acute myeloid leukemia; targeted therapies; early phase trials acute myeloid leukemia; targeted therapies; early phase trials
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Assouline, S.; Cocolakis, E.; Borden, K.L.B. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers 2012, 4, 1161-1179.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top